Shanghai Junshi Biosciences Co., Ltd. (1877.HK)
Develops cancer and immune disease drugs through clinical trials in China.
18.56+0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-24.4%
The outlook
Analysts are solidly bullish on Junshi Biosciences with a strong-buy consensus and an average price target about 55% above current levels. However, the stock is trading well below both its 50- and 200-day moving averages and sits near the lower end of its 52-week range, reflecting recent weakness. The disconnect between analyst optimism and the stock's current technical positioning leaves the outlook mixed.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 4 analysts
Price trendBelow its 50- & 200-day averages
52-week range14% of the way from its 52-week low to high
Price targetAvg target +55% vs current price
Analyst price target
~12-month · 4 analysts28.85average target+55.4% vs now
Now 18.56
Low 20.00High 31.97
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$19.04B
52-wk high
38.64
52-wk low
15.25
50-day avg
18.78
200-day avg
22.47
Trailing P/E
—